Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 11/20 | 0.39 |
| ▸ | CTSS | P25774 | 10/20 | 0.39 |
| ▸ | CTSB | P07858 | 9/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7859105 | 0.99 | EPHX2 (0.43) | EPHX2CTSKCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7857531 | 0.95 | EPHX2 (0.44) | EPHX2CYP2C19CTSLNPC1RAB9A | |
| SCHEMBL7855762 | 0.91 | EPHX2 (0.43) | EPHX2CTSKCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7848736 | 0.87 | EPHX2 (0.41) | EPHX2CTSKCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13636880 | 0.86 | EPHX2 (0.43) | EPHX2CYP3A4CYP2C9CYP2C19NPC1 | |
| SCHEMBL7856575 | 0.85 | EPHX2 (0.39) | EPHX2CTSKCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7856662 | 0.84 | CTSK (0.40) | CTSKCYP3A4CYP2C9CYP2C19CTSL | |
| SCHEMBL7848775 | 0.83 | CTSL (0.39) | CTSKCYP3A4CYP2C9CYP2C19CTSL | |
| SCHEMBL7856659 | 0.82 | HTT (0.44) | CTSKCYP3A4CYP2C9CYP2C19CTSL | |
| SCHEMBL7856656 | 0.82 | EPHX2 (0.43) | EPHX2NPC1RAB9AADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009132453-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1I | EPHX2 4171/4885CTSK 647/4885CYP3A4 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.